Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 15;146(1):21–35. doi: 10.1161/CIRCULATIONAHA.121.056805

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors.

Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 3. — Disease associations of lipid class-specific FA abundances. P values and hazard ratios from models adjusted for age (as underlying time variable), sex, waist circumference, height, leisure time physical activity, smoking status, alcohol intake, highest achieved education level, fasting status at blood draw, total energy intake, blood pressure (systolic and diastolic), blood lipids (total cholesterol, high-density lipoprotein cholesterol, and standard clinical triacylglycerol), antihypertensive medication, lipid-lowering medication, acetylsalicylic acid medication, and respective class sum. Models for CVD further adjusted for antidiabetic medication and proportion glycohemoglobin. A, Scatter plot of P values for type 2 diabetes vs CVD; all labeled points were statistically significant after accounting for multiple testing. B, Hazard ratios (95% CI) of all significant associations after controlling for multiple testing in A. CE indicates cholesteryl esters; Cer, ceramides; CVD, cardiovascular disease; DG, diacylglycerols; dhCer, dihydroceramides; FA, fatty acids; FFA, free fatty acids; HexCer, hexosylceramides; LacCer, lactosylceramides; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines; MG, monoacylglycerols; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PEO, phosphatidylethanolamine ether; PEP, phosphatidylethanolamine plasmalogen; PI, phosphatidylinositol; SM, sphingomyelins; and TG, triacylglycerols.